Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Completed · Phase 3

Conditions studied: Diabetes Mellitus, Type 2

In brief

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

Key facts

Study ID

NCT00094991

Run by

Bristol-Myers Squibb

People needed

42

Starts

2004-05-01

Expected to finish

2006-05-01

Last updated by the study team

2010-09-14

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes;
• Serum triglyceride concentration < or = 600 mg/dL;
• Body mass index < or = 37 kg/m2

You may not qualify if…

• Type 1 diabetes;
• History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;
• Congestive heart failure (NYHA Class III and IV);
• Uncontrolled hypertension;
• Women of Child Bearing Potential
• History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease

Where it is running

• Local Institution — San Antonio, Texas, United States
• Local Institution — Pisa, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.